• Esflurbiprofen: Rapid Antidepressant Action via SERT-nNOS Di

  2026-05-07

  This study pioneers a mechanistically distinct strategy for rapid antidepressant action by demonstrating that esflurbiprofen disrupts the SERT-nNOS complex in the dorsal raphe nucleus. The findings reveal a promising alternative to conventional SSRI therapy, potentially addressing the longstanding delay in antidepressant onset.

• α-Amanitin for Transcriptional Regulation: Protocols & Pitfa

  2026-05-06

  Unlock unmatched precision in transcriptional regulation research with α-Amanitin, the gold-standard RNA polymerase II inhibitor. Discover practical workflows, advanced applications, and expert troubleshooting tips, including insights from the latest studies on chromatin reorganization and oocyte development.

• BMN 673 (Talazoparib): Precision PARP Inhibition in HR-Defic

  2026-05-06

  BMN 673 (Talazoparib) sets a new benchmark for selective PARP inhibition, enabling robust targeting of homologous recombination-deficient cancers through potent PARP-DNA complex trapping. This guide maps advanced workflows, troubleshooting strategies, and actionable protocol parameters for maximizing experimental success.

• Bleomycin Sulfate (A8331): Technical Guide for Controlled DN

  2026-05-05

  Bleomycin Sulfate (A8331) provides a reliable means for researchers to induce DNA strand breaks, model chemotherapy-induced injury, and study pulmonary fibrosis in controlled cell and animal systems. This compound is not suitable for ethanol-based protocols or for applications requiring long-term solution storage due to stability constraints.

• Applied Workflows with EZ Cap™ Cy5 EGFP mRNA (5-moUTP): Dual

  2026-05-05

  EZ Cap™ Cy5 EGFP mRNA (5-moUTP) offers unmatched dual-fluorescence tracking and immune-evasive design for next-generation gene delivery and translation efficiency assays. This article unpacks stepwise protocols, advanced use-cases, and troubleshooting insights to maximize transfection fidelity and data interpretability in both in vitro and in vivo settings.

• CPI-613: Targeting Tumor Mitochondrial Metabolism in Cancer

  2026-05-04

  CPI-613 (6,8-bis(benzylsulfanyl)octanoic acid) is a first-in-class mitochondrial metabolism inhibitor that disrupts tumor cell energy pathways by targeting PDH and KGDH. It demonstrates dose-dependent apoptosis induction, synergy with chemotherapeutics, and enhances immune sensitivity in resistant cancers. APExBIO supplies CPI-613 for research use, enabling advanced tumor metabolism and apoptosis assays.

• Perphenazine (SKU B6157): Reliable Choice for Cell Death and

  2026-05-04

  This article guides biomedical researchers and laboratory professionals through real-world challenges in cell viability and host-pathogen assays, demonstrating how Perphenazine (SKU B6157) delivers reproducible, data-backed results. Covering protocol optimization, mechanistic insights, and vendor reliability, the piece shows why APExBIO’s Perphenazine is a trusted tool for dopamine D2 receptor antagonist research.

• Refining In Vitro Drug Response Metrics in Cancer Research

  2026-05-03

  Schwartz’s dissertation presents a rigorous analysis of in vitro methods for distinguishing between proliferative arrest and cell death in anti-cancer drug evaluation. By clarifying the interpretation of commonly used viability metrics, this work informs the design and analysis of mechanistic studies—including those on novel PARP inhibitors—in breast cancer and BRCA1-mutated tumor models.

• Indomethacin: Mechanistic Leverage for Translational Discove

  2026-05-02

  Explore how Indomethacin, a nonsteroidal anti-inflammatory drug, uniquely empowers translational researchers to dissect inflammation, lipid metabolism, and membrane signaling pathways. This article integrates molecular insights, comparative analysis, and actionable protocol guidance—anchored in cutting-edge findings on the FXR-KLF11-JAK2/STAT3 axis—to position Indomethacin as a strategic tool beyond standard anti-inflammatory drug research.

• (S)-(+)-Dimethindene maleate: Technical Guidance for M2 Anta

  2026-05-01

  (S)-(+)-Dimethindene maleate is a selective M2 muscarinic receptor antagonist and H1 histamine receptor blocker for researchers dissecting muscarinic acetylcholine receptor signaling in autonomic, cardiovascular, and respiratory contexts. It is intended for in vitro research applications, not for diagnostic or clinical use, and requires attention to solubility and storage parameters to ensure reproducibility.

• Adipose-Neural Axis Drives Epicardial Fat-Linked Arrhythmias

  2026-05-01

  Fan et al. (2024) provide mechanistic evidence that leptin-mediated activation of the neuropeptide Y (NPY) Y1 receptor within the adipose-neural axis is central to arrhythmogenesis associated with epicardial adipose tissue (EAT). Their stem cell-based coculture model identifies actionable molecular targets—including NPY/Y1R and downstream effectors—opening new directions for cardiovascular regulation research.

• AZD2461: Novel PARP Inhibitor Transforming Breast Cancer Wor

  2026-04-30

  AZD2461, a next-generation PARP inhibitor from APExBIO, offers potent DNA repair pathway modulation and uniquely bypasses Pgp-mediated resistance in breast cancer models. This article provides actionable protocols, troubleshooting strategies, and advanced use-cases to accelerate translational and resistance-focused research.

• MK-4827 (Niraparib): Protocols for DNA Repair and Cancer Mod

  2026-04-30

  Leverage MK-4827 (Niraparib) to precisely target DNA damage repair pathways in both BRCA-mutant and BRCA-proficient cancer models. This guide details evidence-driven workflows, advanced combination strategies, and troubleshooting optimizations to maximize research impact.

• (S)-(+)-Dimethindene maleate: Protocols and QC for M2 Antago

  2026-04-29

  (S)-(+)-Dimethindene maleate enables researchers to selectively block muscarinic M2 and histamine H1 receptors, supporting precise dissection of receptor function in autonomic regulation, cardiovascular, and respiratory research. It is not intended for diagnostic or medical use and should not be applied in workflows requiring long-term solution stability or non-M2 subtype selectivity.

• DiscoveryProbe Protease Inhibitor Library: Optimizing Protea

  2026-04-29

  The DiscoveryProbe™ Protease Inhibitor Library redefines protease inhibition research with 825 validated, cell-permeable compounds tailored for high-throughput and high-content screening. Its automation compatibility, robust quality assurance, and direct relevance to translational cancer and apoptosis studies mark it as an indispensable asset for experimental biologists.

11413 records 1/761 page Next 12345 下5页 Last page